New Approaches to the Immunotherapy of Cancer Using Interleukin-2

A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone

1987 • 2,769 citations

Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer

1985 • 2,616 citations

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1976 • 2,458 citations

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

1982 • 2,228 citations

A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating Lymphocytes

1986 • 1,787 citations

Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced Cancer

1987 • 1,224 citations

Structure and expression of a cloned cDNA for human interleukin-2

1983 • 1,176 citations

Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

1985 • 737 citations

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1984 • 687 citations

Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coli

1984 • 600 citations

In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

1985 • 600 citations

Novel Interleukin-2 Receptor Subunit Detected by Cross-Linking Under High-Affinity Conditions

1986 • 585 citations

Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.

1986 • 534 citations

Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor.

1981 • 516 citations

Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta.

1985 • 492 citations

Expression of interleukin 2 receptors on activated human B cells.

1984 • 488 citations

Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma.

1987 • 478 citations

High-Dose Recombinant Interleukin 2 in the Treatment of Patients With Disseminated Cancer

1986 • 459 citations

The Neuropsychiatric Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells

1987 • 456 citations

Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line.

1980 • 436 citations

Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.

1983 • 414 citations

Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

1985 • 376 citations

In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

1985 • 368 citations

Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials

1987 • 361 citations

Clinical effects and toxicity of interleukin-2 in patients with cancer

1986 • 359 citations

The fate of interleukin-2 after in vivo administration.

1983 • 358 citations

Lymphokine-activated killer cells: A new approach to immunotherapy of cancer

1985 • 314 citations

Cancer Immunotherapy Using Interleukin-2 and Interleukin-2-Activated Lymphocytes

1986 • 307 citations

Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

1988 • 302 citations

Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes

1987 • 301 citations

Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

1984 • 299 citations

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

1985 • 293 citations

In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.

1980 • 264 citations

Stimulation of oligodendroglial proliferation and maturation by interleukin-2

1986 • 251 citations

Characterization of the human receptor for T-cell growth factor.

1983 • 240 citations

"Anomalous" THY-1(+) killer cells in allogeneic and F1-anti-parental mixed leukocyte culture. Relation to natural killer cells and allospecific cytotoxic T lymphocytes

1982 • 237 citations

T-cell-derived helper factor allows in vivo induction of cytotoxic T cells in nu/nu mice

1980 • 228 citations

The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors.

1980 • 223 citations

Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.

1985 • 212 citations

Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.

1987 • 211 citations

Effects of Interleukin-2 on Renal Function in Patients Receiving Immunotherapy for Advanced Cancer

1987 • 170 citations

Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients

1987 • 166 citations

Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.

1985 • 157 citations

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.

1986 • 149 citations

The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2

1986 • 145 citations

Dermatologic Changes Associated With Interleukin 2 Administration

1987 • 142 citations

The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma.

1984 • 137 citations

Detection and functional studies of p60-65 (Tac antigen) on activated human B cells.

1984 • 136 citations

Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.

1985 • 136 citations

Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancer

1985 • 130 citations

The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression.

1987 • 129 citations

Adoptive immunotherapy of cancer: accomplishments and prospects.

1984 • 120 citations

Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells

1984 • 116 citations

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.

1986 • 110 citations

Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.

1986 • 108 citations

T cell factor (interleukin 2) allows in vivo induction of T helper cells against heterologous erythrocytes in athymic (nu/nu) mice

1980 • 107 citations

Interleukin 2 receptors are expressed by alveolar macrophages during pulmonary sarcoidosis and are inducible by lymphokine treatment of normal human lung macrophages, blood monocytes, and monocyte cell lines.

1987 • 105 citations

Induction of human T lymphocyte motility by interleukin 2.

1985 • 98 citations

Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.

1987 • 97 citations

Lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with lectins.

1982 • 94 citations

Evidence that lymphokine-activated killer cells and natural killer cells are distinct based on an analysis of congenitally immunodeficient mice.

1985 • 93 citations

Intraperitoneal Administration of Interleukin-2 in Patients With Cancer

1986 • 91 citations

Systemic administration of recombinant human interleukin-2 in mice.

1984 • 85 citations

Systemic administration of interleukin-2 in humans.

1984 • 78 citations

Interleukin 2 receptors on cultured murine epidermal Langerhans cells.

1986 • 75 citations

Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.

1986 • 75 citations

Identification of T cell lymphoma tumor antigens on human T cell lines

1976 • 74 citations

Comparison of the biological activities of human recombinant interleukin-2(125) and native interleukin-2.

1985 • 62 citations

Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin.

1983 • 62 citations

Effect of anti-B16 melanoma monoclonal antibody on established murine B16 melanoma liver metastases.

1987 • 61 citations

IN VIVO ADMINISTRATION OF INTERLEUKIN-2 ENHANCES SPECIFIC ALLOIMMUNE RESPONSES

1983 • 58 citations

Results of Clinical Trials with the Administration of Interleukin 2 and Adoptive Immunotherapy with Activated Cells in Patients with Cancer

1986 • 57 citations

Interferon-gamma enhances induction of lymphotoxin in recombinant interleukin 2-stimulated peripheral blood mononuclear cells.

1985 • 56 citations

In vivo administration of purified Jurkat-derived interleukin 2 in mice.

1984 • 52 citations

Mitogen responsiveness and inhibitory activity of mesenteric lymph node cells

1982 • 32 citations

Restoration of allograft responsiveness in B rats by interleukin 2 and/or adherent cells.

1982 • 31 citations

Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.

1986 • 26 citations

Inhibition of cytotoxic T-cell clonal expansion by cyclophosphamide and the recovery of cytotoxic T-lymphocyte precursors by supernatants from mixed-lymphocyte cultures.

1981 • 21 citations

Differential expression of lymphokine-activated killer cells and natural killer cells in adoptive transfer experiments utilizing fractionated bone marrow.

1986 • 10 citations

Identification and expansion of human lymphokine-activated killer cells: Implications for the immunotherapy of cancer

1987 • 7 citations

The effects of interleukin-2 (IL-2) on primary in vivo immune responses

1982 • 5 citations

Pathophysiologic Effects of Interleukin-2 on Renal Function in 135 Patients Receiving Immunotherapy for Advanced Cancer

1987 • 2 citations